PCSK9remmers

PCSK9 inhibitors are a class of drugs used to lower low-density lipoprotein (LDL) cholesterol levels. They work by targeting a protein called PCSK9 (proprotein convertase subtilisin/kexin type 9). This protein plays a role in regulating the number of LDL receptors on the surface of liver cells. LDL receptors are responsible for removing LDL cholesterol from the bloodstream. PCSK9 binds to these receptors and leads to their degradation, thus reducing the liver's ability to clear LDL cholesterol.

PCSK9 inhibitors, typically monoclonal antibodies, bind to PCSK9 and prevent it from interacting with LDL receptors. This allows more LDL receptors to remain on the liver cell surface, leading to increased uptake and removal of LDL cholesterol from the blood. This mechanism results in a significant reduction in LDL cholesterol levels, often by 50% or more, in addition to statin therapy.

These medications are usually administered via subcutaneous injection, with dosing schedules varying depending on the specific drug. PCSK9 inhibitors are generally prescribed for individuals with very high LDL cholesterol levels who have not achieved adequate control with maximum-tolerated statin therapy, or for those with familial hypercholesterolemia or established atherosclerotic cardiovascular disease. While generally well-tolerated, potential side effects can include injection site reactions, nasopharyngitis, and, rarely, allergic reactions. Their long-term cardiovascular benefits are supported by clinical trial data demonstrating a reduction in major adverse cardiovascular events.